Real-world clinical scenarios during introduction of trastuzumab biosimilar for HER2-positive breast cancer in the European Union

1. Wyrwicz, L.
2. Rodríguez Sánchez, C.A.
3. Sánchez-Rovira, P.
4. Lewis, S.
5. Sandschafer, D.
6. San, T.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.2217/FON-2023-0421 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

•